Zymeworks Balance Sheet Health
Financial Health criteria checks 6/6
Zymeworks has a total shareholder equity of $464.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $580.9M and $116.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$374.33m |
| Equity | US$464.81m |
| Total liabilities | US$116.07m |
| Total assets | US$580.88m |
Recent financial health updates
Recent updates
Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
Apr 18Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments
Mar 05Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion
Feb 06Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind
Jan 31Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M
Nov 08Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone
Oct 26Zymeworks: A Roller Coaster Year
Jul 26Zymeworks And The Blue Falcon Elucidation
May 17Zymeworks Inc. (NYSE:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 27
We Think Zymeworks (NYSE:ZYME) Can Afford To Drive Business Growth
Nov 17Zymeworks: Drop Due To Low Differentiation Against Competition
Jul 05Zymeworks: Oncology Drug Discovery Company With Major Big Pharma Deals
Dec 11Zymeworks' zanidatamab nabs Breakthrough Therapy tag for biliary tract cancer
Nov 30Zymeworks' zanidatamab an Orphan Drug in Europe for gastric cancer
Nov 19Financial Position Analysis
Short Term Liabilities: ZYME's short term assets ($412.9M) exceed its short term liabilities ($55.8M).
Long Term Liabilities: ZYME's short term assets ($412.9M) exceed its long term liabilities ($60.3M).
Debt to Equity History and Analysis
Debt Level: ZYME is debt free.
Reducing Debt: ZYME had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ZYME has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ZYME has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 2.9% each year